Table 1.

PFS and RR of tivozanib and sorafenib.

Patient group	N (subjects)		PFS (months)		HR	RR
	Tivo	Sor	Tivo	Sor		Tivo (%)	Sor (%)
ITT	175	175	5.6	3.9	0.73	18	8
Prior axitinib in 3rd-line subgroup	47	46	5.5	3.9	0.71	16	6
Prior axitinib in 4th-line subgroup	36	43	5.5	3.6	0.64	11	10
Prior axitinib in 3rd- or 4th-line subgroup	83	89	5.5	3.7	0.68	13	8

Abbreviations: PFS, progression-free survival; HR, hazard ratio; RR, response rate; Tivo, tivozanib; sor, sorafenib; ITT, intention to treat.